Epitomee Medical Shares Surge 110% as New CEO Sparks Market Confidence
Epitomee Medical shares surged 15% on the Tel Aviv Stock Exchange, exceeding a 110% gain over three days following the appointment of new CEO Dolev Rafaeli. The company aims to revitalize its innovative weight-loss pill through direct-to-consumer digital channels.
Shares of Epitomee Medical, an Israeli weight-loss pill developer founded by entrepreneur Shimon Eckhouse, surged by 15% on the Tel Aviv Stock Exchange, marking a dramatic rally of over 110% across the last three trading sessions. The sudden market enthusiasm comes despite the company releasing no fresh corporate developments, sparking intense interest among investors.
The catalyst behind the rally is the recent appointment of Dolev Rafaeli as the company's new CEO. Rafaeli brings a proven track record in turning around medical device companies, most notably Photomedex. Investors appear to be placing their confidence in his leadership to unlock the commercial potential of the Israeli-developed capsule.
Innovative Mechanical Solution for Weight Loss
"Epitomee's problem has never been the product itself, but rather its distribution channels," Rafaeli stated. Despite the current surge, the company has shed roughly 90% of its market value since its 2021 initial public offering during the peak of the market boom.
Epitomee offers a non-pharmacological alternative to weight-loss injections and drugs. The company developed a tiny, ingestible mechanical capsule packed inside a pill. Once it reaches the stomach, the capsule absorbs fluids and expands into a rigid structure, exerting gentle pressure on the stomach wall to create a sensation of fullness before a meal.
The capsule, designed to be taken twice daily, remains in the stomach for a few hours before passing into the intestines and disintegrating within minutes. This modern approach avoids the complications of traditional gastric balloons, which required invasive medical procedures for insertion and removal.
Strategic Shift and Commercial Outlook
Epitomee holds a significant advantage with clearance from the United States Food and Drug Administration (FDA) following successful clinical trials. The company initially went public at a valuation of 632 million shekels, surging to 1 billion shekels shortly after following a commercialization agreement with global food giant Nestlé. However, in 2023, Nestlé canceled the partnership, arguing that the product failed to meet its internal targets, triggering a sharp decline in share price.
"Epitomee holds 70 patents and all necessary regulatory approvals, including the FDA, and now we need to bring it to market. My goal is to reach 20,000 to 30,000 new users in the U.S., generating about $50 million in sales," Rafaeli noted.
Rafaeli plans to bypass traditional distributors, pivoting instead to direct-to-consumer marketing via a dedicated application. Consumers will be able to place orders, obtain online prescriptions, and receive home deliveries directly.
Capitalizing on the broader weight-loss market boom created by injectable drugs, Epitomee aims to capture users who discontinue injections due to side effects. As a medical device rather than a systemic drug, the product is already available in Israel at Super-Pharm for 890 shekels, with plans for subsidized pricing through health maintenance organization supplementary insurance programs.
